Nitric oxide donor drugs: current status and future trends

Bibliography

• FURCHGOTT RE ZAWADZKI JV: The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature (1980) 288:373–376.
   PubMed Web of Science ®Google Scholar
• PALMER RI\4J, FERRIGE AG, MONCADA S: Nitric oxide release accounts for the biological activity of EDRF. Nature (1987) 327:524–526.
   PubMed Web of Science ®Google Scholar
• RADOMSKI MW, PALMER RI\4J, MONCADA S: Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet (1987) 2:1057–1058.
   PubMed Web of Science ®Google Scholar
• RADOMSKI MW, PALMER RI\4J, MONCADA S: The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem. Biophys. Res. Commun. (1987) 148:1482–1489.
   PubMed Web of Science ®Google Scholar
• RADOMSKI MW, PALMER RI\4J, MONCADA S: The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br: J. Pharmacol (1987) 92:639–646.
   Google Scholar
• BATH PMW, HASSALL DG, GLADWIN AM, PALMER RMJ, MARTIN JF: Nitric-oxide and prostacyclin - divergence of inhibitory effects on monocyte chemotaxis and adhesion to endothelium M vitro. Arteriosclec Thromb. (1991) 11:254–260.
   PubMed Web of Science ®Google Scholar
• HICKEY MJ, KUBES P: Role of nitric oxide in regulation of leucocyte-endothelial cell interactions. Exp. Physiol (1997) 82:339–348.
   PubMed Web of Science ®Google Scholar
• GARG UC, HASSID A: Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J. Clin. Invest. (1989) 83:1774–1777.
   PubMed Web of Science ®Google Scholar
• ZHANG J, SNYDER SH: Nitric oxide in the nervous system. Ann. Rev Pharmacol Toxicol (1995) 35:213–233.
   PubMed Web of Science ®Google Scholar
• MONCADA S, PALMER RI\4J, HIGGS EA: Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev. (1991) 43:109–142.
   PubMed Web of Science ®Google Scholar
• STUEHR DJ, KWON NS, NATHAN CF, GRIFFITH OW, FELDMAN PL, WISEMAN J: N-hydroxy-L-arginine is an intermediate in the biosynthesis of NO from L-arginine. Biol Chem. (1991) 266:6259–6263.
   Web of Science ®Google Scholar
• KNOWLES RG, MONCADA S: Nitric oxide synthases in mammals. Biochem. (1994) 298:249–258.
   Web of Science ®Google Scholar
• LUOMA JS, STRALIN P, MARKLUND SL, HILTUNENE TP, SARKIOJA T, YLA-HRTTUALA S: Expression of extracellular SOD and iNOS in macrophages and smooth muscle cells in human and rabbit atherosclerotic lesions. Colocalization with epitopes characteristic of oxidized LDL and peroxynitrite-modified proteins. Arteriosclec Thromb. Vasc. Biol. (1998) 18:157–167.
   PubMed Web of Science ®Google Scholar
• GRIFFITHS OW, STUEHR DJ: Nitric oxide synthases: properties and catalytic mechanism. Ann. Rev Physiol (1995) 57:707–736.
   PubMed Web of Science ®Google Scholar
• ABU-SOUD HM, STUEHR DJ: Nitric oxide synthases reveal a role for calmodulin in controlling electron transfer. Proc. Nati Acad. Sci. USA (1993) 90:10769–10772.
   PubMed Web of Science ®Google Scholar
• XIA Y, ROMAN LJ, MASTER SS, ZWEIER JL: Inducible nitric oxide synthase generates superoxide from the reductase domain. J. Biol. Chem. (1998) 273:22635–22639.
   PubMed Web of Science ®Google Scholar
• DENNINGER JW, MARLETTA MA: Guanylate cyclase and the NO/cGMP signaling pathway. Biochim. Biophys. Acta (1999) 1411:334–350.
   PubMed Web of Science ®Google Scholar
• WALDMAN S, MURAD F: cGMP synthesis and function. Pharmacol Rev (1987) 39:163–196.
   PubMed Web of Science ®Google Scholar
• MARTIN E, LEE YC, MURAD F: YC-1 activation of human soluble guanylyl cyclase has both heme-dependent and heme-independent components. Proc. Natl. Acad. Sci. USA (2001) 98:12938–12942.
   PubMed Web of Science ®Google Scholar
• STASCH JP, BECKER EM, Alonso-Alija C et al.: NO-independent regulatory site on soluble guanylate cyclase. Nature (2001) 410:212–5.
   PubMed Web of Science ®Google Scholar
• PAOLOCCI N, EKELUND UEG, ISODA T et al.: cGMP-independent inotropic effects of nitric oxide and peroxynitrite donors: potential role for nitrosylation. Am. J. Physiol (2000) 279:H1982–H1988.
   Web of Science ®Google Scholar
• YOUNG DV, SEREBRYANIK D, TAM SW: Suppression of human coronary artery smooth muscle cell proliferation by nitric oxide is cGMP-independent. FASEB (2000) 14:372.
   Web of Science ®Google Scholar
• HELLER R, POLACK T, GRABNER R, TILL U: Nitric oxide inhibits proliferation of human endothelial cells via a mechanism independent of cGMP. Atherosclerosis (1999) 144:49–57.
   PubMed Web of Science ®Google Scholar
• SUMMERS BA, OVERHOLT JL, PRABHAKAR NR: Nitric oxide inhibits L-type Ca2+ current in glomus cells of the rabbit carotid body via a cGMP-independent mechanism. J. Neurophysiol. (1999) 81:1449–1457.
   PubMed Web of Science ®Google Scholar
• SOGO N, MAGID KS, SHAW CA, WEBB DJ, MEGSON IL: Inhibition of human platelet aggregation by nitric oxide donor drugs: relative contribution of cGMP-independent mechanisms. Biochem. Biophys. Res. Commun. (2000) 279:412–419.
   PubMed Web of Science ®Google Scholar
• BROWN G: Nitric oxide and mitochondrialrespiration. Biochim. Biophys. Acta (1999) 1411:351–369.
   PubMed Web of Science ®Google Scholar
• DUSTING GJ, MACDONALD PS: Nitric oxide in cardiovascular disease and transplantation. Annals Med. (1995) 27:395–406.
   PubMed Web of Science ®Google Scholar
• BENNETT BM, MCDONALD BJ, NIGAM R, SIMON WC: Biotransformation of organic nitrates and vascular smooth muscle cell function. Trends Pharmacol. Sci. (1994) 15:245–249.
   PubMed Web of Science ®Google Scholar
• HAYWARD CS, MACDONALD PS, KEOGH AM: Inhaled nitric oxide in cardiology. Expert Opin. Investig. Drugs (2001) 10(11):1947–1956.
   PubMed Web of Science ®Google Scholar
• LEHMANN J: Nitric oxide donors - current trends in therapeutic applications. Expert Opin. Invest. Patents (2000) 10:559–574.
   Web of Science ®Google Scholar
• LAIGHT DW: Nitric oxide therapy for cardiovascular disease. Expert Opin. Titer: Patents (2001) 11(6):999–1005.
   Web of Science ®Google Scholar
• MILLER AA, MEGSON IL, GRAY GA: Inducible nitric oxide synthase-derived superoxide contributes to hypereactivity in small mesenteric arteries from a rat model of chronic heart failure. Br: J. Pharmacol. (2000) 131:29–36.
   PubMed Web of Science ®Google Scholar
• MCDONALD KK, ZHARIKOV S, BLOCK ER, KILBERG MS: A caveolar complex between the cationic amino acid transporter 1 and endothelial nitric oxide synthase may explain the `arginine paradox'. Biol Chem. (1997) 272:31213–31216.
   Web of Science ®Google Scholar
• WASCHER TC, POSCH K, WALLNER S,HERMETTER A, KOSTNER GM, GRAIER WF: Vascular effects of L-arginine: anything beyond a substrate for the NO- synthase? Biochem. Biophys. Res. Commun. (1997) 234:35–38.
   PubMed Web of Science ®Google Scholar
• VALLANCE P, LEONE A, CALVER A, COLLIER J, MONCADA S: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet (1992) 339:572–576.
   PubMed Web of Science ®Google Scholar
• BOGER RH, BODE-BOGER SM, SZUBA A et al.: Asymmetric dimethylarginine (ADMA): A novel risk factor for endothelial dysfunction - Its role in hypercholesterolemia. Circulation (1998) 98:1842–1847.
   PubMed Web of Science ®Google Scholar
• RAITAKARI OT, PAIVA H, LAINE H, LAAKSONEN R, LAAKSO J, KNUUTI J: Plasma asymmetric dimethylarginine (ADMA) and myocardial vasodilatory function in young subjects with borderline hypertension or familial hypercholesterolaemia. Eur. Heart J. (2001) 22:651–651.
   Web of Science ®Google Scholar
• KIELSTEIN JT, FROLICH JC, HALLERH, FLISER D: ADMA (asymmetric dimethylarginine): an atherosclerotic disease mediating agent in patients with renal disease? Nephrol. Dial. Transplant. (2001) 16:1742–1745.
   Web of Science ®Google Scholar
• COOKE JP: Does ADMA cause endothelial dysfunction? Arterioscler. Thromb. Vasc. Biol. (2000) 20:2032–2037.
   PubMed Web of Science ®Google Scholar
• BULT H, HERMAN AG, MATTHYS KE: Antiatherosclerotic activity of drugs in relation to nitric oxide function. Eur. Pharmacol. (1999) 375:157–176.
   PubMed Web of Science ®Google Scholar
• VELIANOU JL, SUWAIDI JAI, LERMAN A: L-arginine: a novel therapy for coronary disease? Expert Opin. Investig. Drugs (1999) 8(11):1785–1793.
   Google Scholar
• SESSA WC: Can modulation of endothelial nitric oxide synthase explain the vasculoprotective actions of statins? Trends Mol. Med (2001) 7:189–191.
   Web of Science ®Google Scholar
• MUECK AO, SEEGER H, WALLWIENER D: Further evidence for direct vascular actions of statins: Effect on endothelial nitric oxide synthase and adhesion molecules. Exp. Clin. Endocrinol. Diabet. (2001) 109:181–183.
   PubMed Web of Science ®Google Scholar
• ADAMSON RH: Hydroxyguanidine-a new antitumour drug. Nature (1972) 236:400–401.
   PubMed Web of Science ®Google Scholar
• CHERN J-W, LEU Y-L, WANG S-S et al:Synthesis and cytotoxic evaluation of substituted sulfonyl-N-hydroxyguanidine derivatives as potential antitumour agents. J. Med. Chem. (1997) 40:2276–2286.
   PubMed Web of Science ®Google Scholar
• HAINSWORTH JD, HANDE KR, SATTERLEE WG et al.: Phase I clinical study of N-[(4-clorophenyl)amino]carbony1-2,3-dihdro-1H-indene-5-sulfonamide (LY186641). Cancer Res. (1989) 49:5217–5220.
   PubMed Web of Science ®Google Scholar
• HANDE KR, KUTTESCH J, HAMILTON M et al.: Kinetics of N-[(4-clorophenyl)amino]carbonyl-2,3-dihdro-1H-indene-5-sulfonamide (LY186641) in humans. Cancer Res. (1990) 50:3910–3914.
   PubMed Web of Science ®Google Scholar
• MUNSHI NC, SEITZ DE, FOSELLA F, LIPPMAN SM, EINHORN LH: Phase II study of sulofenur (LY186641), a novel antineoplastic agent, in advanced non-small cell lung cancer. Proc. Am. Assoc. Cancer Res. (1991) 32:189.
   Google Scholar
• BRIEN ME, HARDY J, TANS et al: A Phase II study of sulofenur, a novel sulfonyl-urea, in recurrent epithelial ovarian cancer. Cancer Chemother. Pharmacol. (1992) 30:245–248.
   PubMed Web of Science ®Google Scholar
• EVERETT SA, PATEL KB, DENNIS MF, SMITH KA, STRATFORD MRL, WARDMAN P: Oxidative denitrification of the antitumour drug hydroxyguanidine. Free Rad. Biol. Med. (1998) 24:1–10.
   PubMed Web of Science ®Google Scholar
• ABRAMS J: Pharmacology of nitroglycerin and long-acting nitrates. Am. J. Cardiol. (1985) 56:12A–18A.
   Google Scholar
• DUPUIS J, LALONDE G, LEMIEUX R, ROULE JL: Tolerance to intravenous nitroglycerin in patients with congestive heart failure: role of increased intravascular volume, neurohumoral activation and lack of prevention with N-acetylcysteine. J. Am. Cardiol. (1990) 16:923–931.
   Web of Science ®Google Scholar
• MUNZEL T, GIAID A, KURZ S, STEWART DJ, HARRISON DG: Evidence for a role of endothelins and protein kinase C in nitroglycerin tolerance. Proc. Natl. Acad. Sci. USA (1995) 92:5244–5248.
   PubMed Web of Science ®Google Scholar
• PARKER JD, FARRELL B, FENTON T, COHANIM M, PARKER JO: Counter-regulatory responses to continuous and intermittent therapy with nitroglycerin. Circulation (1991) 84:2336–2345.
   PubMed Web of Science ®Google Scholar
• MUNZEL T, SAYEGH H, FREEDMAN BA, TARPEY MM, HARRISON DG: Evidence for enhanced vascular superoxide anion production in nitrate tolerance: a novel mechanism underlying tolerance and cross-tolerance. J. Clin. Invest. (1995) 95:187–194.
   PubMed Web of Science ®Google Scholar
• KOJDA G, HACKER A, NOACK E: Effects of nonintermittent treatment of rabbits with pentaerythritol tetranitrate on vascular reactivity and superoxide production. Eur: Pharmacol. (1998) 355:23–31.
   PubMed Web of Science ®Google Scholar
• JURT U, GORI T, RAVANDI A, BABAEI S, ZEMAN P, PARKER JD: Differential effects of pentaerythritol tetranitrate and nitroglycerin on the development of tolerance and evidence of lipid peroxidation: A human in vivo study. I. Am. Coll. Cardiol (2001) 38:854–859.
   PubMed Web of Science ®Google Scholar
• HACKER A, MULLER S, MEYER W, KOJDA G: The nitric oxide donor pentaerythritol tetranitrate can preserve endothelial function in established atherosclerosis. Br. J. Pharmacol (2001) 132:1707–1714.
   PubMed Web of Science ®Google Scholar
• VAN BORTEL LM, SPEK JJ, BALKESTEIN EJ, SARDINA M, STRUIJKER BOUDIER HA: Is it possible to develop drugs that act more selectively on large arteries?' Hypertens. (1999) 17:701–705.
   Google Scholar
• MONZANI MV, COLTRO G, SALA A, SARDINA M: Pharmacokinetics of ITF 296 (Sinitrodil) a novel nitrate in healthy volunteers. Ear. Pharm. ScL (1999) 7:179–184.
   PubMed Web of Science ®Google Scholar
• WANG S, FEELISCH M, HARRISON DG, SELLKE FW: Preferential dilation of large coronary microvessels by the mononitrates SPM-477 and SPM-5185. Cardiovasc. Pharmacol (1996) 27:587–593.
   PubMed Web of Science ®Google Scholar
• ARNET U, YANG ZH, SIEBENMANN R et al.: Development of nitrate tolerance in human arteries and veins - comparison of nitroglycerin and SPM-5185. Cardiovasc. Pharmacol (1995) 26:401–406.
   PubMed Web of Science ®Google Scholar
• HERMANN M, KAPIOTIS S, HOFBAUER R et al.: Salicylate inhibits LDL oxidation initiated by superoxide/nitric oxide radicals. FEBS Lett. (1999) 445:212–214.
   PubMed Web of Science ®Google Scholar
• BLAYLOCK MG, CUTHBERTSON BH, GALLEY HF, FERGUSON NR, WEBSTER NR: The effect of nitric oxide and peroxynitrite on apoptosis in human polymorphonuclear leukocytes. Free Rad. Biol. Med. (1998) 25:748–752.
   PubMed Web of Science ®Google Scholar
• PENG W, HOIDAL JR, FARRUKH IS: Regulation of the Ca2+-activated K+ channels in pulmonary vascular smooth muscle cells: role of nitric oxide. J. Appl. Physiol (1996) 81:1264–1272.
   PubMed Web of Science ®Google Scholar
• PLANE F, HURRELL A, JEREMY JY, GARLAND CJ: Evidence that potassium channels make a major contribution to SIN-1-evoked relaxation of rat isolated mesenteric artery. Br: J. Pharmacol (1996) 119:1557–1562.
   Google Scholar
• FEELISCH M, OSTROWSKI J, NOACK E: On the mechanism of NO release from sydnonimines. I Cardiovasc. Pharmacol (1989) 14 (Suppl. 11):513–522.
   Google Scholar
• MESSIN R, BOXHO G, DE SMEDT J, BUNTINX IM: Acute and chronic effect of molsidomine extended release on exercise capacity in patients with stable angina, a double-blind crossover clinical trial versus placebo. I. Cardiovasc. Pharmacol (1995) 25:558–563.
   PubMed Web of Science ®Google Scholar
• DANCHIN N, JULLIEREY, ANCONINA J, PERRIN 0, SELTON-SUTY C, CHERRIER F: Comparative effects of oral molsidomine and nifedipine on methylergometrine-induced coronary artery spasm. Am. J. Cardiol (1991) 67:1208–1211.
   PubMed Web of Science ®Google Scholar
• UNGER P, VACHIERY JL, DE CANNIERE D, STAROUKINE M, BERKENBOOM G: Comparison of the hemodynamic responses to molsidomine and isosorbide dinitrate in congestive heart failure. Am. Heart (1994) 128:557–563.
   PubMed Web of Science ®Google Scholar
• LEHMANN G, REINIGER G, BEYERLE A, ZEITLER H, RUDOLPH W: Haemodynamic evaluation of two regimens of molsidomine in patients with chronic congestive heart failure. Eur: f Clin. Pharmacol (1995) 48:109–114.
   PubMed Web of Science ®Google Scholar
• The ESPRIM trial: short-term treatment of acute myocardial infarction with molsidomine. European Study of Provention of Infarct with Molsidomine (ESPRIM) Group. Lancet (1994) 344:91–97.
   PubMed Web of Science ®Google Scholar
• GERZER R, DRUMMER C, KARRENBROCK B, HEIM J-M: Inhibition of platelet activating factor-induced platelet aggregation by molsidomine, SIN-1, and nitrates in vitro and ex vivo. J. Cardiovasc. Pharmacol (1989) 14 (Suppl. 11):S115–S119.
   Google Scholar
• BULT H, FRET HRL, HERMAN AG: Interaction between SIN-1 and prostacyclin in inhibiting platelet aggregation." Cardiovasc. Pharmacol (1989) 14 (Suppl. 11):S120–S123.
   Google Scholar
• GROVES P, LEWIS MJ, CHEADLE HA, PENNY WJ: SIN-1 reduces platelet adhesion and platelet thrombus formation in a porcine model of balloon angioplasty. Circulation (1993) 87:590–597.
   PubMed Web of Science ®Google Scholar
• PROVOST P, TREMBLAY J, MERHI Y: The anti-adhesive and antithrombotic effects of the nitric oxide donor SIN-1 are combined with adecreased vasoconstriction in a porcine model of balloon angioplasty. Arterioscler: Thromb. Vase. Biol. (1997) 17:1806–1812.
   Google Scholar
• JUST M, MARTORANA PA: Effect of molsidomine on thrombus formation in stenosed coronary arteries of dogs and pigs." Cardiovasc. Pharmacol (1989) 14 (Suppl. 11):S129–S136.
   Google Scholar
• RIKITAKE Y, HIRATA K, KAWASHIMA S,AKITA H, YOKOYAMA M: Inhibitory effect of inducible type nitric oxide synthase on oxidative modification of low density lipoprotein by vascular smooth muscle cells. Atherosclerosis (1998) 136:51–57.
   PubMed Web of Science ®Google Scholar
• GROVES PH, BANNING HP, PENNY WJ, NEWBY AC, CHEADLE HA, LEWIS MI: The effects of exogenous nitric oxide on smooth muscle cell proliferation following porcine carotid angioplasty. Cardiovasc. Res. (1995) 30:87–96.
   PubMed Web of Science ®Google Scholar
• DE MEYER GR, BULT H, KOCKX MM, HERMAN AG: The effect of chronic treatment with NO donors during intimal thickening and fatty streak formation. Biofactors (1997) 6:209–215.
   PubMed Web of Science ®Google Scholar
• DE MEYER GR, BULT H, USTUNES L, KOCKX MM, FEELISCH M, HERMAN AG: Effect of nitric oxide donors on neointima formation and vascular reactivity in the collared carotid artery of rabbits. J. Cardiovasc. Pharmacol (1995) 26:272–279.
   PubMed Web of Science ®Google Scholar
• CLARK SC, SUDERSHAN C, ROUGHAN J, FLECKNELL PA, DARK JH: Modulation of reperfusion injury after single lung transplantation by pentoxifylline, inositol polyanions and SIN-1. f Thome. Cardiovasc. Surg. (1999) 117:556–564.
   PubMed Web of Science ®Google Scholar
• JOHNSON D, FREISCHLAG JA, LESNIAK R et al.: Endothelial damage due to ischemia and reperfusion is prevented with SIN-1. Cardiovasc. Surg. (1998) 6:527–532.
   PubMedGoogle Scholar
• HOLM P, KANKAANRANTA H, METSA-KETELA T, MOILANEN E: Radical releasing properties of nitric oxide donors GEA 3162, SIN-1 and S-nitroso-N-acetypenicillamine. Ear. I Pharmacol (1998) 346:97–102.
   PubMed Web of Science ®Google Scholar
• KANKAANRANTA H, RYDELL E, PETERSSON A-S et at Nitric oxide-donating properties of mesoionic 3-aryl substituted oxatriazole-5-imine derivatives. Br. J. Pharmacol (1996) 117:401–406.
   PubMed Web of Science ®Google Scholar
• SCHMIDT K, SCHRAMMEL A, GORREN ACF, KOESLING D, MAYER B: Decomposition of the 'NO-donor' GEA 3162 results in the formation of peroxynitrite. Naunyn-Schmiedebergs Arch. Pharmacol (2001) 363:161.
   PubMed Web of Science ®Google Scholar
• NURMINEN M-J, VAPAATALO H: Effect of intracerebroventricular and intravenous administration of nitric oxide donors on blood pressure and heart rate on anaesthetized rats. Br. J. Pharmacol (1996) 119:1422–1426.
   PubMed Web of Science ®Google Scholar
• GRENEGARD M, GUSTAFSSON MC, ANDERSSON RGG, BENGTSSON T: Synergistic inhibition of thrombin-induced platelet aggregation by the novel nitric oxide donor GEA 3175 and adenosine. Br. Pharmacol (1996) 118:2140–2144.
   PubMed Web of Science ®Google Scholar
• VIRTA M, KARP M, VUORINEN P: Nitricoxide donor-mediated killing of bioluminescent Eschericia coli. Antimicrob. Agents Chemother. (1994) 38:2775–2779.
   PubMed Web of Science ®Google Scholar
• WANIKIAT P, WOODWARD DF, ARMSTRONG RA: Investigation of the role of nitric oxide and cyclic GMP in both the activation and inhibition of human neutrophils. Br. Phannacol (1997) 122:1135–1145.
   Web of Science ®Google Scholar
• FORSLUND T, SUNDQVIST T: Nitric oxide-releasing particles inhibit phagocytosis in human neutrophils. Biochem. Biophys. Res. Commun. (1997) 233:492–495.
   PubMed Web of Science ®Google Scholar
• WARD C, WONG TH, MURRAY J et al: Induction of human neutrophil apoptosis by nitric oxide donors: evidence for a caspase-dependent, cyclic GMP-independent, mechanism. Biochem. Pharmacol (2000) 59:305–314.
   PubMed Web of Science ®Google Scholar
• TAYLOR EL, MEGSON IL, HASLETT C, ROSSI AG: Dissociation of DNA fragmentation from other hallmarks of apoptosis in nitric oxide-treated neutrophils: differences between individual nitric oxide donor drugs. Biochem. Biophys. Res. Commun. (2001) 289:1229–1236.
   PubMed Web of Science ®Google Scholar
• MORLEY D, KEEFER LK: Nitric oxide/ nucleophile complexes: a unique class of nitric oxide-based vasodilators.' Cardiovasc. Pharmacol (1993) 22\(Suppl. 7):53–59.
   Google Scholar
• KEEFER LK, FLIPPEN-ANDERSON JL,GEORGE C et al.: Chemistry of the diazeniumdiolates - 1. Structural and spectral characteristics of the [N(0)NO] (-) functional group. Nitric Oxide (2001) 5:377–394.
   Google Scholar
• RAMAMURTHI A, LEWIS RS: Measurement and modeling of nitric oxide release rates for nitric oxide donors. Chem. Res. Toxicol (1997) 10:408–413.
   PubMed Web of Science ®Google Scholar
• HORSTMANN A, MENZEL L, GABLER R, JENTSCH A, URBAN W, LEHMANN J: Release of nitric oxide from novel diazeniumdiolates monitored by laser magnetic resonance spectroscopy. Nitric Oxide (2002) 6:135–41.
   PubMed Web of Science ®Google Scholar
• SMITH DJ, SIMMONS ML: Transdermal delivery of nitric oxide from diazeniumdiolates.j Controlled Release (1998) 51:153–159.
   PubMed Web of Science ®Google Scholar
• MOORADIAN DL, HUTSELL TC, KEEFER LK: Nitric oxide (NO) donor molecules: effect of NO release rate on vascular smooth muscle cell proliferation in vitro.' Cardiovasc. Pharmacol (1995) 25:674–678.
   PubMed Web of Science ®Google Scholar
• YIN ZL, DUSTING GJ: A nitric oxide donor (spermine-NONOate) prevents formation of neointima in rabbit carotid artery. Clin. Exp. Pharmacol Physiol (1997) 24:436–438.
   PubMed Web of Science ®Google Scholar
• PLUTA RM, OLDFIELD EH, BOOCK RJ: Reversal and prevention of cerebral vasospasm by intracarotid infusions of nitric oxide donors in a primate model of subarachnoid hemorrhage.' Neurawrg. (1997) 87:746–751.
   Google Scholar
• DU ZY, HICKS M, JANSZ P, RAINER S, SPRATT P, MACDONALD P: The nitric oxide donor, diethylamine NONOate, enhances preservation of the donor rat heart. J. Heart Lung Trans. (1998) 17:1113–1120.
   PubMed Web of Science ®Google Scholar
• BRILLI RJ, KRAFTE-JACOBS B, SMITH DJ et al.: Intratracheal instillation of a novel NO/nucleophile adduct selectively reduces pulmonary hypertension. .1. Appl Physiol (1997) 83:1968–1975.
   Google Scholar
• WU XJ, TANG XP, XIAN M, WANG PG: Glycosylated diazeniumdiolates: a novel class of enzyme- activated nitric oxide donors. Tetrahedron Lett. (2001) 42:3779–3782.
   Web of Science ®Google Scholar
• TANG XP, XIAN M, TRIKHA M, HONN KV, WANG PG: Synthesis of peptide-diazeniumdiolate conjugates: towards enzyme activated antitumor agents. Tetrahedron Lett. (2001) 42:2625–2629.
   Web of Science ®Google Scholar
• WILLIAMS DLH: S-nitrosation and the reactions of S-nitroso compounds. Chem. Soc. Rev (1985) 14:171–196.
   Web of Science ®Google Scholar
• SCHARFSTEIN JS, KEANEY JF, SLIVKA A et al.: In vivo transfer of nitric oxide between a plasma protein-bound reservoir and low molecular weight thiols. Clin. Invest. (1994) 94:1432–1439.
   Google Scholar
• STAMLERJS, JARAKI 0, OSBORNE J et al.: Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. Proc. Nati Acad. ScL USA (1992) 89:7674–7677.
   Google Scholar
• STAMLERJS, SIMON DI, OSBORNE J et al.: S-Nitrosylation of proteins with nitric oxide: synthesis and characterisation of biologically active compounds. Proc. Nati Acad. Sci. USA (1992) 89:444–448.
   PubMed Web of Science ®Google Scholar
• MARLEY R, PATEL RP, ORIE N, CEASER E, DARLEY-USMAR V, MOORE K: Formation of nanomolar concentrations of S-nitrosoalbumin in human plasma by nitric oxide. Free Radic. Biol. Med. (2001) 31:688–696.
   PubMed Web of Science ®Google Scholar
• GOW AJ, STAMLER JS: Reactions between nitric oxide and haemoglobin under physiological conditions. Nature (1998) 391:169–173.
   PubMed Web of Science ®Google Scholar
• JIA L, BONAVENTURA C, BONAVENTURA J, STAMLER JS: S-Nitrosohaemoglobin: a dynamic activity of blood involved in vascular control. Nature (1996) 380:221–226.
   PubMed Web of Science ®Google Scholar
• PAWLOSKI JR, HESS DT, STAMLER JS: Export by red blood cells of nitric oxide bioactivity. Nature (2001) 409:622–626.
   PubMed Web of Science ®Google Scholar
• GLADWIN MT, SHELHAMER JH, SCHECHTER AN et al.: Role of circulating nitrite and S-nitrosohemoglobin in the regulation of regional blood flow in humans. Proc. Natl. Acad. Sci. USA (2000) 97:11482–11487.
   PubMed Web of Science ®Google Scholar
• RADOMSKI MW, REES DD, DUTRA A,MONCADA S: S-Nitroso-glutathioneinhibits platelet aggregation M vitro and M vivo. Br. Pharmacol (1992) 107:745–749.
   PubMed Web of Science ®Google Scholar
• DE BELDER AJ, MACALLISTER R, RADOMSKI MW, MONCADA S, VALLANCE P: Effects of S-nitroso-glutathione in the human forearm circulation: evidence for selective inhibition of platelet activation. Cardiovasc. Res. (1994) 28:691–694.
   PubMed Web of Science ®Google Scholar
• DICKS AP, SWIFT HR, WILLIAMS DLH, BUTLER AR, AL-SA'DONI HH, COX BG: Identification of Cu+ as the effective reagent in nitric oxide formation from 5-nitrosothiols (RSNO). J. Chem. Soc. Perkin Trans]. (1996) 2:481–487.
   Google Scholar
• AL-SA'DONI HH, MEGSON IL, BISLAND SK, BUTLER AR, FLITNEY FW: Neocuproine, a selective Cu(I) chelator, reversibly inhibits relaxation of rat vascular smooth muscle by 5-nitrosothiols. Br. Pharmacol (1997) 121:1047–1050.
   PubMed Web of Science ®Google Scholar
• ASKEW SC, BARNETT DJ, MCANINLY J, WILLIAMS DLH: Catalysis by Cu of nitric oxide release from S-nitrosothiols (RSNO). J. Chem. Soc. Perkin Trans. (1995) 2:741–745.
   Google Scholar
• HOLMES AJ, WILLIAMS DL: Reaction of S-nitrosothiols with ascorbate: clear evidence of two reactions. Chem. Comm. (1998) 16:1711–1712.
   Web of Science ®Google Scholar
• JOURD'HEUIL D, LAROUX FS, MILES AM, WINK DA, Grisham MB: Effect of superoxide dismutase on the stability of S-nitrosothiols. Arch. Biochem. Biophys. (1999) 361:323–330.
   PubMed Web of Science ®Google Scholar
• GORDGE MP, MEYER DJ, HOTHERSHALL J, NEILD GH, PAYNE NN, NORONHA-DUTRA A: Role of a copper (I)-dependent enzyme in the anti-platelet action of S-nitrosoglutathione. Br. Pharmacol. (1996) 114:1083–1089.
   Web of Science ®Google Scholar
• FREEDMAN JE, FREI B, WELCH GN, LOSCALZO J: Glutathione perwddase potentiates the inhibition of platelet function by S-nitrosothiols.J. Clin. Invest. (1995) 96:394–400.
   PubMed Web of Science ®Google Scholar
• ZAI A, RUDD A, SCRIBNER AW, LOSCALZO J: Cell-surface protein disulfide isomerase catalyzes transnitrosation and regulates intracellular transfer of nitric oxide. Clin. Invest. (1999) 103:393–399.
   Google Scholar
• TRUJILLO M, ALVAREZ MN, PELUFFO G, FREEMAN BA, RADI R: Xanthine oxidase-mediated decomposition of S-nitrosothiols." Biol. Chem. (1998) 273:7828–7834.
   PubMed Web of Science ®Google Scholar
• ASKEW SC, BUTLER AR, FLITNEY FW, KEMP GD, MEGSON IL: Chemical mechanism underlying the vasodilator and platelet anti-aggregating properties of S-nitroso-N-acetyl-D,L-penicillamine and S-nitrosoglutathione. Bioorg. Med. Chem. (1995) 3:1–9.
   PubMed Web of Science ®Google Scholar
• MEYER DJ, KRAMER H, OZER N, COLES B, KETTERER: Kinetics and equilibria of S-nitrosothiol-thiol exchange between glutathione, cysteine, penicillamines and serum albumin. FEBS Lett. (1994) 345:177–178.
   PubMed Web of Science ®Google Scholar
• MELINO G, BERNASSOLA F, KNIGHT RA, CORASANITI MT, NISTICO G, FINAZZI-AGRO A: S-nitrosylation regulates apoptosis. Nature (1997) 388:432–433.
   PubMed Web of Science ®Google Scholar
• LIU L, HAUSLADEN A, ZENG M, QUE L, HEITMAN J, STAMLERJS: A metabolic enzyme for S-nitrosothiol conserved from bacteria to humans. Nature (2001) 410:490–493.
   PubMed Web of Science ®Google Scholar
• KOPPITZ KM, SCHUSDZIARRA V, ALLESCHER HD: Evidence for a feedback inhibition of NO synthesis in enteric synaptosomes via a nitrosothiol intermediate. Am. J. Physiol. (1999) 277:G875–G844.
   Web of Science ®Google Scholar
• MEGSON IL, SOGO N, MAZZEI FA, BUTLER AR, WALTON JC, WEBB DJ: Inhibition of human platelet aggregation by a novel S-nitrosothiol is abolished by haemoglobin and red blood cells M vitro: implications for anti-thrombotic therapy. Br. Pharmacol. (2000) 131:1391–1398.
   PubMed Web of Science ®Google Scholar
• MACALLISTER RJ, CALVER AL, RIEZEBOS J, COLLIER J, VALLANCE P: Relative potency of nitrovasodilators on human blood vessels: an insight into the targetting of nitric oxide delivery.' Pharmacol. Exp. Ther. (1995) 273:1529–1537.
   PubMed Web of Science ®Google Scholar
• LANGFORD EJ, BROWN AS, WAINWRIGHT RJ et al.: Inhibition of platelet activity by S-nitrosoglutathione during coronary angioplasty. Lancet (1994) 344:1458–1460.
   PubMed Web of Science ®Google Scholar
• LANGFORD EJ, WAINWRIGHT RJ, MARTIN JF: Platelet activation in acute myocardial infarction and unstable angina is inhibited by nitric oxide donors. Arteriosclec Thromb. Vasc. Biol. (1996) 16:51–55.
   PubMed Web of Science ®Google Scholar
• MOLLOY J, MARTIN JF, BASKERVILLE PA, FRASER SCA, MARKUS HS: S- nitrosoglutathione reduces the rate of embolization in humans. Circulation (1998) 98:1372–1375.
   PubMed Web of Science ®Google Scholar
• BAUER JA, FUNG HL: Differential hemodynamic effects and tolerance properties of nitroglycerin and an S-nitrosothiol in experimental heart failure.' Pharmacol. Exp. Ther. (1991) 256:249–254.
   PubMed Web of Science ®Google Scholar
• MILLER MR, ROSEBERRY MJ, MAZZEI FA, BUTLER AR, WEBB DJ, MEGSON IL: S-nitrosothiols do not induce tolerance and are not cross-tolerant in rat femoral arteries. Eui: Pharmacol. (2000) 408:335–343.
   PubMed Web of Science ®Google Scholar
• JAWORSKI K, KINARD F, GOLDSTEIN D et al.: S-nitrosothiols do not induce oxidative stress, contrary to other nitric oxide donors, in cultures of vascular endothelial or smooth muscle cells. Eur: Pharmacol. (2001) 425:11–19.
   PubMed Web of Science ®Google Scholar
• BATTINELLI E, WILLOUGHBY SR, FOXALL T, VALERI CR, LOSCALZO J: Induction of platelet formation from megakaryocytoid cells by nitric oxide. Proc. Nati Acad. Sci. USA (2001) 98:14458–14463.
   PubMed Web of Science ®Google Scholar
• MARKS DS, VITA JA, FOLTS JD, KEANEY JF, WELCH GN, LOSCALZO J: Inhibition of neointimal proliferation in rabbits after vascular injury by a single treatment with a protein adduct of nitric oxide." Gin. Invest. (1995) 96:2630–2638.
   PubMed Web of Science ®Google Scholar
• MAALEJ N, ALBRECHT R, LOSCALZO J, FOLTS JD: The potent platelet inhibitory effects of S-nitrosated albumin coating of artificial surfaces.' Am. Coll. Cardiol. (1999) 33:1408–1414.
   PubMed Web of Science ®Google Scholar
• MEGSON IL, GREIG IR, GRAY GA, WEBB DJ, BUTLER AR: Prolonged effect of a novel S-nitrosated glyco-amino acid in endothelium-denuded rat femoral arteries: potential as a slow release nitric oxide donor drug. Br. Pharmacol. (1997) 122:1617–1624.
   PubMed Web of Science ®Google Scholar
• SOGO N, CAMPANELLA C, WEBB DJ, MEGSON IL: S-Nitrosothiols cause prolonged, nitric oxide-mediated relaxation in human saphenous vein and internal mammary artery: therapeutic potential in bypass surgery. Br. Pharmacol. (2000) 131:1236–1244.
   PubMed Web of Science ®Google Scholar
• SOGO N, WILKINSON IB, MACCALLUM H et al.: A novel S-nitrosothiol (RIG200) causes prolonged relaxation in dorsal hand veins with damaged endothelium. Clin. Pharmacol. Ther. (2000) 68:75–81.
   PubMed Web of Science ®Google Scholar
• DEL SOLDATO P, SORRENTINO R, PINTO A: NO-aspirins: a class of new antiinflammatory and antithrombotic agents. Trends Pharmacol. Sci. (1999) 20:319–323.
   PubMed Web of Science ®Google Scholar
• NAPOLI C, CIRINO G, DEL SOLDATO P et al.: Effects of nitric oxide-releasing aspirin versus aspirin on restenosis in hypercholesterolemic mice. Proc. Nati Acad. Sci. USA (2001) 98:2860–2864.
   Google Scholar
• WAINWRIGHT CL, MILLER AM, WORK LM, DEL SOLDATO P: NCX4016 (NO-asprin) reduces infarct size and suppresses arrythmias following myocardial ischaemia/reperfusion in pigs. Br. Pharmacol. (2002) 135:1882–1888.
   PubMed Web of Science ®Google Scholar
• MOMI S, EMERSON M, PAUL W et al.: Prevention of pulmonary thromboembolism by NCX 4016, a nitric oxide-releasing aspirin. Eur. Pharmacol. (2000) 397:177–185.
   PubMed Web of Science ®Google Scholar
• FREDDUZZI S, MARIUCCI G, TANTUCCI M, DEL SOLDATO P, AMBROSINI MV: Nitro-aspirin (NCX4016) reduces brain damage induced by focal cerebral ischemia in the rat. Neurosci. Lett. (2001) 302:121–124.
   PubMed Web of Science ®Google Scholar
• BANDARAGE UK, CHEN L, FANG X et al.: Nitrosothiol esters of diclofenac: synthesis and pharmacoligical characterization as gastrointestinal-sparing prodrugs.j. Med. Chem. (2000) 43:4005–4016.
   PubMed Web of Science ®Google Scholar
• ROSSINI G, MUSCARA MN, CIRINO G, WALLACE J: Inhibition of cyclo-oxygenase- 2 exacerbates ischaemia-induced acute myocardial dysfunction in the rabbit. Br. Pharmacy] (2002) 135:1540–1546.
   PubMed Web of Science ®Google Scholar
• ASADA H, NANJO T, ITOH T, SUZUKI H, KURIYAMA H: Effects of 3,4-dihydro-8-(2-hydroxy-3-isopropylaminopropoxy)-3-nitroxy- 2H-1-bezopyran (K-351) on smooth muscle cells and neuromuscular transmission in guinea-pig vascular tissues. Pharmacol Exp. The]: (1982) 223:560–72.
   Google Scholar
• KOU K, KURIYAMA H, SUZUKI H: Effects of 3,4-dihydro 8 (2 hydroxy-3-isopropylaminopropoxy)-3-nitroxy- 2H-1-benzopyran (K-351) on smooth muscle cells and neuromuscular transmission in the canine mesenteric artery. Br. Pharmacy] (1982) 77:679–89.
   PubMed Web of Science ®Google Scholar
• NOGUCHI K, SAKANASHI M: Effects of nipradilol on myocardial ischaemia produced by coronary stenosis in dogs. Br. Pharmacol (1987) 91:411–9.
   PubMed Web of Science ®Google Scholar
• KISHIDA H, SAITO T, NEJIMA J et al.: Evaluation of a new antianginal agent, nipradilol, in effort angina using holter monitoring. fpn. Heart j (1988) 29:309–17.
   PubMed Web of Science ®Google Scholar
• HANEDA T, ICHIHARA K, ONODERA S: Effects of nicorandil and nipradilol on ischemic myocardium in perfused rat heart. Eur.j PharmacoL (1989) 162:81–7.
   PubMed Web of Science ®Google Scholar
• THAKUR NK, HAYASHI T, SUMI D et al.: Anti-Atherosclerotic Effect of beta-Blocker with Nitric Oxide-Releasing Action on the Severe Atherosclerosis. Cardiovasc. Pharmacol (2002) 39:298–309.
   PubMed Web of Science ®Google Scholar
• STAMLER JS, SIMON DI, JARAKI 0 et al.: S-Nitrosylation of Tissue-Type Plasminogen-Activator Confers Vasodilatory and Antiplatelet Properties on the Enzyme. Proc. Natl. Acad. Sci. USA (1992) 89:8087–8091.
   Google Scholar
• DELYANI JA, NOSSULI TO, SCALIA R, THOMAS G, GARVEY DS, LEFER AM: S-Nitrosylated tissue-type plasminogen activator protects against myocardial ischemia/reperfusion injury in cats: Role of the endothelium. I Pharmacy] Exp. Met: (1996) 279:1174–1180.
   PubMed Web of Science ®Google Scholar
• GUREVITZ 0, ELDAR M, SKUTELSKY E et al.: S-nitrosoderivative of a recombinant fragment of von Willebrand factor (5-nitroso-AR545C) inhibits thrombus formation in guinea pig carotid artery thrombosis model. Thromb. Haemost. (2000) 84:912–917.
   Google Scholar
• DARDIK R, VARON D, ESKARAEV R, TAMARIN T, INBAL A: Recombinant fragment of von Willebrand factor AR545C inhibits platelet binding to thrombin and platelet adhesion to thrombin-treated endothelial cells. Br. .1. Haemato] (2000) 109:512–518.
   PubMed Web of Science ®Google Scholar
• BOHL KS, WEST JL: Nitric oxide-generating polymers reduce platelet adhesion and smooth muscle cell proliferation. Biomaterials (2000) 21:2273–2278.
   PubMed Web of Science ®Google Scholar
• ESAKI T, HAYASHI T, MUTO E et al.: Expression of inducible nitric oxide synthase and Fas/Fas ligand corrolates with the incidence of apoptotic cell death in atheromatous plaques of human coronary arteries. Nitric Oxide (2000) 4:561–571.
   PubMed Web of Science ®Google Scholar
• ITOH M, TAKENAKA K, OKAZAKI R, TAKEDA N, TOKITOH N: The first stable aromatic S-nitrosothiol: Synthesis, structure and reactivity. Chem. Lett. (2001):1206–1207.
   Web of Science ®Google Scholar
• MEGSON IL, MORTON S, GREIG IR et al.: N-Substituted analogues of S-nitroso-N-acetyl-D,L-penicillamine: chemical stability and prolonged nitric oxide mediated vasodilatation in isolated rat femoral arteries. Br: J. Pharmacol (1999) 126:639–648.
   PubMed Web of Science ®Google Scholar
• MEHTA SR, YUSUF S, PETERS RJ et al: Effects of pretreatment with clopidogrel and aspirin followed by long- term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet (2001) 358:527–33.
   PubMed Web of Science ®Google Scholar